Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Basilea Pharmaceutica ( (CH:BSLN) ).
Basilea Pharmaceutica announced that the US Biomedical Advanced Research and Development Authority (BARDA) has approved an additional $39 million in funding to support the development of its novel antifungal agents, Fosmanogepix and BAL2062. This funding will aid ongoing and upcoming Phase 3 and Phase 2 studies, addressing the high medical need for new antifungal treatments, especially for patients with weakened immune systems.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
More about Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company founded in 2000, focusing on developing innovative drugs to combat severe bacterial and fungal infections. The company has successfully launched hospital-use drugs, Cresemba for invasive fungal infections and Zevtera for bacterial infections, and is listed on the Swiss stock exchange.
Average Trading Volume: 37,672
Current Market Cap: CHF569.8M
Find detailed analytics on BSLN stock on TipRanks’ Stock Analysis page.